All Studies Meta Analysis Recent:

Bioactive compounds from Huashi Baidu decoction possess both antiviral and anti-inflammatory effects against COVID-19

Xu et al., Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2301775120

Apr 2023

Post
Facebook

Source PDF All Studies Meta AnalysisMeta

Quercetin for COVID-19

22nd treatment shown to reduce risk in July 2021

^*, now known with p = 0.0031 from 11 studies.

Lower risk for ICU admission, hospitalization, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine complementary and synergistic treatments. ^* >10% efficacy in meta analysis with ≥3 clinical studies.

4,000+ studies for 60+ treatments. c19early.org

In Vitro study of compounds from Huashi Baidu (Q-14), showing dose-dependent inhibition of SARS-CoV-2 with quercetin. Authors also perform a mouse study showing that Q-14 decreases SARS-CoV-2 viral load and reduces pulmonary inflammation.

Among 60 compounds, six (magnolol, glycyrrhisoflavone, licoisoflavone A, emodin, echinatin, and quercetin) showed dose-dependent inhibition of SARS-CoV-2, including two M^pro inhibitors (echinatin and quercetin) and two RdRp inhibitors (glycyrrhisoflavone and licoisoflavone A).

Followup studies Xu, Yan collectively show that quercetin and echinatin had only weak SARS-CoV-2 protease inhibition in SDS-PAGE assays Xu, but false positive FRET results from MCA-AVLQ quenching Xu, Yan. Authors note that the compounds may act via other targets to achieve reported anti-COVID-19 effects Xu, and underscore the importance of meticulous validation with multiple assays when identifying SARS-CoV-2 protease inhibitors Xu, Yan.

52 preclinical studies support the efficacy of quercetin for COVID-19:

31 In Silico studies Ahmed, Akinwumi, Alanzi, Alavi, Alkafaas, Azmi, Chandran, Chellasamy, Corbo, El-Megharbel, Hasanah, Ibeh, Kandeil, Mandal, Moschovou, Nguyen, Pan, Qin, Rehman, Sai Ramesh, Sekiou, Shaik, Singh, Singh (B), Thapa, Wang, Waqas, Yang, Yang (B), Zhang, Şimşek

16 In Vitro studies Aguado, Bahun, DiGuilio, El-Megharbel, Fang, Goc, Kandeil, Munafò, Pan, Roy, Singh (C), Waqas, Wu, Xu (B), Yang, Zhang (B)

5 In Vivo animal studies Aguado, El-Megharbel, Shaker, Wu, Wu (B)

In Silico studies predict inhibition of SARS-CoV-2, or minimization of side effects, with quercetin or metabolites via binding to the spike Note A, Alavi, Azmi (B), Chandran, Kandeil, Mandal, Moschovou, Nguyen, Pan, Thapa (B), Şimşek, M^pro Note B, Akinwumi, Alanzi, Ibeh, Kandeil, Mandal, Moschovou, Nguyen, Qin, Rehman, Sekiou (B), Singh, Thapa (B), Wang, Zhang, Shaik, Waqas, RNA-dependent RNA polymerase Note C, Corbo, PLpro Note D, Ibeh, Zhang, ACE2 Note E, Chandran, Ibeh, Qin, Thapa (B), Şimşek, Alkafaas, TMPRSS2 Note F, Chandran, helicase Note G, Alanzi, Singh (B), endoribonuclease Note H, Alavi, cathepsin L Note I, Ahmed, Wnt-3 Note J, Chandran, FZD Note K, Chandran, LRP6 Note L, Chandran, ezrin Note M, Chellasamy, ADRP Note N, Nguyen, NRP1 Note O, Şimşek, EP300 Note P, Hasanah, PTGS2 Note Q, Qin, HSP90AA1 Note R, Qin, Hasanah, matrix metalloproteinase 9 Note S, Sai Ramesh, IL-6 Note T, Yang, Yang (B), IL-10 Note U, Yang, VEGFA Note V, Yang (B), and RELA Note W, Yang (B) proteins. In Vitro studies demonstrate efficacy in Calu-3 Note X, DiGuilio, A549 Note Y, Yang, HEK293-ACE2+ Note Z, Singh (C), Huh-7 Note AA, Pan, Caco-2 Note AB, Roy, Vero E6 Note AC, Kandeil, El-Megharbel, Roy, mTEC Note AD, Wu, and RAW264.7 Note AE, Wu cells. Animal studies demonstrate efficacy in K18-hACE2 mice Note AF, Aguado, db/db mice Note AG, Wu, Wu (B), BALB/c mice Note AH, Shaker, and rats El-Megharbel (B). Quercetin reduced proinflammatory cytokines and protected lung and kidney tissue against LPS-induced damage in mice Shaker.

Important missing comments or errors? Let us know.

1. Aguado et al., Senolytic therapy alleviates physiological human brain aging and COVID-19 neuropathology, bioRxiv, doi:10.1101/2023.01.17.524329.biorxiv.org, doi.org.

2. Ahmed et al., Evaluation of the Effect of Zinc, Quercetin, Bromelain and Vitamin C on COVID-19 Patients, International Journal of Diabetes Management, doi:10.61797/ijdm.v2i2.259.researchlakejournals.com, doi.org.

3. Akinwumi et al., Evaluation of therapeutic potentials of some bioactive compounds in selected African plants targeting main protease (Mpro) in SARS-CoV-2: a molecular docking study, Egyptian Journal of Medical Human Genetics, doi:10.1186/s43042-023-00456-4.springeropen.com, doi.org.

4. Alanzi et al., Structure-based virtual identification of natural inhibitors of SARS-CoV-2 and its Delta and Omicron variant proteins, Future Virology, doi:10.2217/fvl-2022-0184.futuremedicine.com, doi.org.

5. Alavi et al., Interaction of Epigallocatechin Gallate and Quercetin with Spike Glycoprotein (S-Glycoprotein) of SARS-CoV-2: In Silico Study, Biomedicines, doi:10.3390/biomedicines10123074.mdpi.com, doi.org.

6. Alkafaas et al., A study on the effect of natural products against the transmission of B.1.1.529 Omicron, Virology Journal, doi:10.1186/s12985-023-02160-6.biomedcentral.com, doi.org.

7. Azmi et al., Utilization of quercetin flavonoid compounds in onion (Allium cepa L.) as an inhibitor of SARS-CoV-2 spike protein against ACE2 receptors, 11th International Seminar on New Paradigm and Innovation on Natural Sciences and its Application, doi:10.1063/5.0140285.scitation.org, doi.org.

8. Azmi (B) et al., The role of vitamin D receptor and IL‐6 in COVID‐19, Molecular Genetics & Genomic Medicine, doi:10.1002/mgg3.2172.wiley.com, doi.org.

9. Bahun et al., Inhibition of the SARS-CoV-2 3CLpro main protease by plant polyphenols, Food Chemistry, doi:10.1016/j.foodchem.2021.131594.sciencedirect.com, doi.org.

10. Chandran et al., Molecular docking analysis of quercetin with known CoVid-19 targets, Bioinformation, doi:10.6026/973206300191081.bioinformation.net, doi.org.

11. Chellasamy et al., Docking and molecular dynamics studies of human ezrin protein with a modelled SARS-CoV-2 endodomain and their interaction with potential invasion inhibitors, Journal of King Saud University - Science, doi:10.1016/j.jksus.2022.102277.sciencedirect.com, doi.org.

12. Corbo et al., Inhibitory potential of phytochemicals on five SARS-CoV-2 proteins: in silico evaluation of endemic plants of Bosnia and Herzegovina, Biotechnology & Biotechnological Equipment, doi:10.1080/13102818.2023.2222196.tandfonline.com, doi.org.

13. DiGuilio et al., Quercetin improves and protects Calu-3 airway epithelial barrier function, Frontiers in Cell and Developmental Biology, doi:10.3389/fcell.2023.1271201.frontiersin.org, doi.org.

14. El-Megharbel et al., Chemical and spectroscopic characterization of (Artemisinin/Quercetin/ Zinc) novel mixed ligand complex with assessment of its potent high antiviral activity against SARS-CoV-2 and antioxidant capacity against toxicity induced by acrylamide in male rats, PeerJ, doi:10.7717/peerj.15638.peerj.com, doi.org.

15. El-Megharbel (B) et al., Chemical and spectroscopic characterization of (Artemisinin/Quercetin/ Zinc) novel mixed ligand complex with assessment of its potent high antiviral activity against SARS-CoV-2 and antioxidant capacity against toxicity induced by acrylamide in male rats, PeerJ, doi:10.7717/peerj.15638.peerj.com, doi.org.

16. Fang et al., Development of nanoparticles incorporated with quercetin and ACE2-membrane as a novel therapy for COVID-19, Journal of Nanobiotechnology, doi:10.1186/s12951-024-02435-2.biomedcentral.com, doi.org.

17. Goc et al., Inhibitory effects of specific combination of natural compounds against SARS-CoV-2 and its Alpha, Beta, Gamma, Delta, Kappa, and Mu variants, European Journal of Microbiology and Immunology, doi:10.1556/1886.2021.00022.akjournals.com, doi.org.

18. Hasanah et al., Decoding the therapeutic potential of empon-empon: a bioinformatics expedition unraveling mechanisms against COVID-19 and atherosclerosis, International Journal of Applied Pharmaceutics, doi:10.22159/ijap.2024v16i2.50128.innovareacademics.in, doi.org.

19. Ibeh et al., Computational studies of potential antiviral compounds from some selected Nigerian medicinal plants against SARS-CoV-2 proteins, Informatics in Medicine Unlocked, doi:10.1016/j.imu.2023.101230.sciencedirect.com, doi.org.

20. Kandeil et al., Bioactive Polyphenolic Compounds Showing Strong Antiviral Activities against Severe Acute Respiratory Syndrome Coronavirus 2, Pathogens, doi:10.3390/pathogens10060758.mdpi.com, doi.org.

21. Mandal et al., In silico anti-viral assessment of phytoconstituents in a traditional (Siddha Medicine) polyherbal formulation – Targeting Mpro and pan-coronavirus post-fusion Spike protein, Journal of Traditional and Complementary Medicine, doi:10.1016/j.jtcme.2023.07.004.sciencedirect.com, doi.org.

22. Moschovou et al., Exploring the Binding Effects of Natural Products and Antihypertensive Drugs on SARS-CoV-2: An In Silico Investigation of Main Protease and Spike Protein, International Journal of Molecular Sciences, doi:10.3390/ijms242115894.mdpi.com, doi.org.

23. Munafò et al., Quercetin and Luteolin Are Single-digit Micromolar Inhibitors of the SARS-CoV-2 RNA-dependent RNA Polymerase, Research Square, doi:10.21203/rs.3.rs-1149846/v1.researchsquare.com, doi.org.

24. Nguyen et al., The Potential of Ameliorating COVID-19 and Sequelae From Andrographis paniculata via Bioinformatics, Bioinformatics and Biology Insights, doi:10.1177/11779322221149622.sagepub.com, doi.org.

25. Pan et al., Quercetin: A promising drug candidate against the potential SARS-CoV-2-Spike mutants with high viral infectivity, Computational and Structural Biotechnology Journal, doi:10.1016/j.csbj.2023.10.029.sciencedirect.com, doi.org.

26. Qin et al., Exploring the bioactive compounds of Feiduqing formula for the prevention and management of COVID-19 through network pharmacology and molecular docking, Medical Data Mining, doi:10.53388/MDM202407003.tmrjournals.com, doi.org.

27. Rehman et al., Natural Compounds as Inhibitors of SARS-CoV-2 Main Protease (3CLpro): A Molecular Docking and Simulation Approach to Combat COVID-19, Current Pharmaceutical Design, doi:10.2174/1381612826999201116195851.doi.org, doi.org.

28. Roy et al., Quercetin inhibits SARS-CoV-2 infection and prevents syncytium formation by cells co-expressing the viral spike protein and human ACE2, Virology Journal, doi:10.1186/s12985-024-02299-w.biomedcentral.com, doi.org.

29. Sai Ramesh et al., Computational analysis of the phytocompounds of Mimusops elengi against spike protein of SARS CoV2 – An Insilico model, International Journal of Biological Macromolecules, doi:10.1016/j.ijbiomac.2023.125553.sciencedirect.com, doi.org.

30. Sekiou et al., In-Silico Identification of Potent Inhibitors of COVID-19 Main Protease (Mpro) and Angiotensin Converting Enzyme 2 (ACE2) from Natural Products: Quercetin, Hispidulin, and Cirsimaritin Exhibited Better Potential Inhibition than Hydroxy-Chloroquine Against COVID-19 Main Protease Active Site and ACE2, ChemRxiv, doi:10.26434/chemrxiv.12181404.v1.chemrxiv.org, doi.org.

31. Sekiou (B) et al., In-Silico Identification of Potent Inhibitors of COVID-19 Main Protease (Mpro) and Angiotensin Converting Enzyme 2 (ACE2) from Natural Products: Quercetin, Hispidulin, and Cirsimaritin Exhibited Better Potential Inhibition than Hydroxy-Chloroquine Against COVID-19 Main Protease Active Site and ACE2, ChemRxiv, doi:10.26434/chemrxiv.12181404.v1.chemrxiv.org, doi.org.

32. Shaik et al., Computational identification of selected bioactive compounds from Cedrus deodara as inhibitors against SARS-CoV-2 main protease: a pharmacoinformatics study, Indian Drugs, doi:10.53879/id.61.02.13859.indiandrugsonline.org, doi.org.

33. Shaker et al., Anti-cytokine Storm Activity of Fraxin, Quercetin, and their Combination on Lipopolysaccharide-Induced Cytokine Storm in Mice: Implications in COVID-19, Iranian Journal of Medical Sciences, doi:10.30476/ijms.2023.98947.3102.ac.ir, doi.org.

34. Şimşek et al., In silico identification of SARS-CoV-2 cell entry inhibitors from selected natural antivirals, Journal of Molecular Graphics and Modelling, doi:10.1016/j.jmgm.2021.108038.sciencedirect.com, doi.org.

35. Singh et al., Unlocking the potential of phytochemicals in inhibiting SARS-CoV-2 M Pro protein - An in-silico and cell-based approach, Research Square, doi:10.21203/rs.3.rs-3888947/v1.researchsquare.com, doi.org.

36. Singh (B) et al., Flavonoids as Potent Inhibitor of SARS-CoV-2 Nsp13 Helicase: Grid Based Docking Approach, Middle East Research Journal of Pharmaceutical Sciences, doi:10.36348/merjps.2023.v03i04.001.kspublisher.com, doi.org.

37. Singh (C) et al., The spike protein of SARS-CoV-2 virus induces heme oxygenase-1: Pathophysiologic implications, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, doi:10.1016/j.bbadis.2021.166322.sciencedirect.com, doi.org.

38. Thapa et al., In-silico Approach for Predicting the Inhibitory Effect of Home Remedies on Severe Acute Respiratory Syndrome Coronavirus-2, Makara Journal of Science, doi:10.7454/mss.v27i3.1609.ac.id, doi.org.

39. Thapa (B) et al., In-silico Approach for Predicting the Inhibitory Effect of Home Remedies on Severe Acute Respiratory Syndrome Coronavirus-2, Makara Journal of Science, doi:10.7454/mss.v27i3.1609.ac.id, doi.org.

40. Wang et al., Computational Analysis of Lianhua Qingwen as an Adjuvant Treatment in Patients with COVID-19, Society of Toxicology Conference, 2023, www.researchgate.net/publication/370491709_Y_Wang_A_E_Tan_O_Chew_A_Hsueh_and_D_E_Johnson_2023_Computational_Analysis_of_Lianhua_Qingwen_as_an_Adjuvant_Treatment_in_Patients_with_COVID-19_Toxicologist_1921_507.researchgate.net.

41. Waqas et al., Discovery of Novel Natural Inhibitors Against SARS-CoV-2 Main Protease: A Rational Approach to Antiviral Therapeutics, Current Medicinal Chemistry, doi:10.2174/0109298673292839240329081008.eurekaselect.com, doi.org.

42. Wu et al., SARS-CoV-2 N protein induced acute kidney injury in diabetic db/db mice is associated with a Mincle-dependent M1 macrophage activation, Frontiers in Immunology, doi:10.3389/fimmu.2023.1264447.frontiersin.org, doi.org.

43. Wu (B) et al., Treatment with Quercetin inhibits SARS-CoV-2 N protein-induced acute kidney injury by blocking Smad3-dependent G1 cell cycle arrest, Molecular Therapy, doi:10.1016/j.ymthe.2022.12.002.sciencedirect.com, doi.org.

44. Xu et al., Reply to Yan et al.: Quercetin possesses a fluorescence quenching effect but is a weak inhibitor against SARS-CoV-2 main protease, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2309870120.pnas.org, doi.org.

45. Xu (B) et al., Bioactive compounds from Huashi Baidu decoction possess both antiviral and anti-inflammatory effects against COVID-19, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2301775120.pnas.org, doi.org.

46. Yan et al., Reframing quercetin as a promiscuous inhibitor against SARS-CoV-2 main protease, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2309289120.pnas.org, doi.org.

47. Yang et al., Active ingredient and mechanistic analysis of traditional Chinese medicine formulas for the prevention and treatment of COVID-19: Insights from bioinformatics and in vitro experiments, Medicine, doi:10.1097/MD.0000000000036238.lww.com, doi.org.

48. Yang (B) et al., In silico evidence implicating novel mechanisms of Prunella vulgaris L. as a potential botanical drug against COVID-19-associated acute kidney injury, Frontiers in Pharmacology, doi:10.3389/fphar.2023.1188086.frontiersin.org, doi.org.

49. Zhang et al., In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus, Journal of Integrative Medicine, doi:10.1016/j.joim.2020.02.005.sciencedirect.com, doi.org.

50. Zhang (B) et al., Discovery of the covalent SARS‐CoV‐2 M^pro inhibitors from antiviral herbs via integrating target‐based high‐throughput screening and chemoproteomic approaches, Journal of Medical Virology, doi:10.1002/jmv.29208.wiley.com, doi.org.

a. The trimeric spike (S) protein is a glycoprotein that mediates viral entry by binding to the host ACE2 receptor, is critical for SARS-CoV-2's ability to infect host cells, and is a target of neutralizing antibodies. Inhibition of the spike protein prevents viral attachment, halting infection at the earliest stage.

b. The main protease or M^pro, also known as 3CL^pro or nsp5, is a cysteine protease that cleaves viral polyproteins into functional units needed for replication. Inhibiting M^pro disrupts the SARS-CoV-2 lifecycle within the host cell, preventing the creation of new copies.

c. RNA-dependent RNA polymerase (RdRp), also called nsp12, is the core enzyme of the viral replicase-transcriptase complex that copies the positive-sense viral RNA genome into negative-sense templates for progeny RNA synthesis. Inhibiting RdRp blocks viral genome replication and transcription.

d. The papain-like protease (PLpro) has multiple functions including cleaving viral polyproteins and suppressing the host immune response by deubiquitination and deISGylation of host proteins. Inhibiting PLpro may block viral replication and help restore normal immune responses.

e. The angiotensin converting enzyme 2 (ACE2) protein is a host cell transmembrane protein that serves as the cellular receptor for the SARS-CoV-2 spike protein. ACE2 is expressed on many cell types, including epithelial cells in the lungs, and allows the virus to enter and infect host cells. Inhibition may affect ACE2's physiological function in blood pressure control.

f. Transmembrane protease serine 2 (TMPRSS2) is a host cell protease that primes the spike protein, facilitating cellular entry. TMPRSS2 activity helps enable cleavage of the spike protein required for membrane fusion and virus entry. Inhibition may especially protect respiratory epithelial cells, buy may have physiological effects.

g. The helicase, or nsp13, protein unwinds the double-stranded viral RNA, a crucial step in replication and transcription. Inhibition may prevent viral genome replication and the creation of new virus components.

h. The endoribonuclease, also known as NendoU or nsp15, cleaves specific sequences in viral RNA which may help the virus evade detection by the host immune system. Inhibition may hinder the virus's ability to mask itself from the immune system, facilitating a stronger immune response.

i. Cathepsin L is a host lysosomal cysteine protease that can prime the spike protein through an alternative pathway when TMPRSS2 is unavailable. Dual targeting of cathepsin L and TMPRSS2 may maximize disruption of alternative pathways for virus entry.

k. The frizzled (FZD) receptor is a host transmembrane receptor that binds Wnt ligands, initiating the Wnt signaling cascade. FZD serves as a co-receptor, along with ACE2, in some proposed mechanisms of SARS-CoV-2 infection. The virus may take advantage of this pathway as an alternative entry route.

l. Low-density lipoprotein receptor-related protein 6 is a cell surface co-receptor essential for Wnt signaling. LRP6 acts in tandem with FZD for signal transduction and has been discussed as a potential co-receptor for SARS-CoV-2 entry.

m. The ezrin protein links the cell membrane to the cytoskeleton (the cell's internal support structure) and plays a role in cell shape, movement, adhesion, and signaling. Drugs that occupy the same spot on ezrin where the viral spike protein would bind may hindering viral attachment, and drug binding could further stabilize ezrin, strengthening its potential natural capacity to impede viral fusion and entry.

n. The Adipocyte Differentiation-Related Protein (ADRP, also known as Perilipin 2 or PLIN2) is a lipid droplet protein regulating the storage and breakdown of fats in cells. SARS-CoV-2 may hijack the lipid handling machinery of host cells and ADRP may play a role in this process. Disrupting ADRP's interaction with the virus may hinder the virus's ability to use lipids for replication and assembly.

o. Neuropilin-1 (NRP1) is a cell surface receptor with roles in blood vessel development, nerve cell guidance, and immune responses. NRP1 may function as a co-receptor for SARS-CoV-2, facilitating viral entry into cells. Blocking NRP1 may disrupt an alternative route of viral entry.

p. EP300 (E1A Binding Protein P300) is a transcriptional coactivator involved in several cellular processes, including growth, differentiation, and apoptosis, through its acetyltransferase activity that modifies histones and non-histone proteins. EP300 facilitates viral entry into cells and upregulates inflammatory cytokine production.

q. Prostaglandin G/H synthase 2 (PTGS2, also known as COX-2) is an enzyme crucial for the production of inflammatory molecules called prostaglandins. PTGS2 plays a role in the inflammatory response that can become severe in COVID-19 and inhibitors (like some NSAIDs) may have benefits in dampening harmful inflammation, but note that prostaglandins have diverse physiological functions.

r. Heat Shock Protein 90 Alpha Family Class A Member 1 (HSP90AA1) is a chaperone protein that helps other proteins fold correctly and maintains their stability. HSP90AA1 plays roles in cell signaling, survival, and immune responses. HSP90AA1 may interact with numerous viral proteins, but note that it has diverse physiological functions.

s. Matrix metalloproteinase 9 (MMP9), also called gelatinase B, is a zinc-dependent enzyme that breaks down collagen and other components of the extracellular matrix. MMP9 levels increase in severe COVID-19. Overactive MMP9 can damage lung tissue and worsen inflammation. Inhibition of MMP9 may prevent excessive tissue damage and help regulate the inflammatory response.

t. The interleukin-6 (IL-6) pro-inflammatory cytokine (signaling molecule) has a complex role in the immune response and may trigger and perpetuate inflammation. Elevated IL-6 levels are associated with severe COVID-19 cases and cytokine storm. Anti-IL-6 therapies may be beneficial in reducing excessive inflammation in severe COVID-19 cases.

u. The interleukin-10 (IL-10) anti-inflammatory cytokine helps regulate and dampen immune responses, preventing excessive inflammation. IL-10 levels can also be elevated in severe COVID-19. IL-10 could either help control harmful inflammation or potentially contribute to immune suppression.

v. Vascular Endothelial Growth Factor A (VEGFA) promotes the growth of new blood vessels (angiogenesis) and has roles in inflammation and immune responses. VEGFA may contribute to blood vessel leakiness and excessive inflammation associated with severe COVID-19.

w. RELA is a transcription factor subunit of NF-kB and is a key regulator of inflammation, driving pro-inflammatory gene expression. SARS-CoV-2 may hijack and modulate NF-kB pathways.

x. Calu-3 is a human lung adenocarcinoma cell line with moderate ACE2 and TMPRSS2 expression and SARS-CoV-2 susceptibility. It provides a model of the human respiratory epithelium, but many not be ideal for modeling early stages of infection due to the moderate expression levels of ACE2 and TMPRSS2.

y. A549 is a human lung carcinoma cell line with low ACE2 expression and SARS-CoV-2 susceptibility. Viral entry/replication can be studied but the cells may not replicate all aspects of lung infection.

z. HEK293-ACE2+ is a human embryonic kidney cell line engineered for high ACE2 expression and SARS-CoV-2 susceptibility.

aa. Huh-7 cells were derived from a liver tumor (hepatoma).

ab. Caco-2 cells come from a colorectal adenocarcinoma (cancer). They are valued for their ability to form a polarized cell layer with properties similar to the intestinal lining.

ac. Vero E6 is an African green monkey kidney cell line with low/no ACE2 expression and high SARS-CoV-2 susceptibility. The cell line is easy to maintain and supports robust viral replication, however the monkey origin may not accurately represent human responses.

ad. mTEC is a mouse tubular epithelial cell line.

ae. RAW264.7 is a mouse macrophage cell line.

af. A mouse model expressing the human ACE2 receptor under the control of the K18 promoter.

ag. A mouse model of obesity and severe insulin resistance leading to type 2 diabetes due to a mutation in the leptin receptor gene that impairs satiety signaling.

ah. A mouse model commonly used in infectious disease and cancer research due to higher immune response and susceptibility to infection.

Xu et al., 24 Apr 2023, China, peer-reviewed, 33 authors. Contact: gaof@im.ac.cn, huangluqi01@126.com.

In Vitro studies are an important part of preclinical research, however results may be very different in vivo.

This Paper Quercetin All

AI generated summary. Current AI models can provide useful summaries for non-experts, but may be inaccurate and have limited ability to analyze larger context such as the entire evidence base for quercetin.

Huashi Baidu decoction (HBF) is a traditional Chinese medicine (TCM) formula that has both antiviral and anti-inflammatory effects.
In this study, the researchers identified six bioactive compounds from HBF that have antiviral and anti-inflammatory effects.
The researchers also found that HBF was able to inhibit the growth of SARS-CoV-2 in cell culture and in mice.

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus.
There are a number of anti-COVID-19 drugs available, but they are not always effective.
Traditional Chinese medicine (TCM) has been shown to be effective in treating COVID-19, and Huashi Baidu decoction (HBF) is a TCM formula that has been shown to have both antiviral and anti-inflammatory effects.
In this study, the researchers identified six bioactive compounds from HBF that have antiviral and anti-inflammatory effects.
These compounds include magnolol, glycyrrhisoflavone, licoisoflavone A, emodin, echinatin, and quercetin.
The researchers also found that HBF was able to inhibit the growth of SARS-CoV-2 in cell culture and in mice.
These findings suggest that HBF could be a promising new treatment for COVID-19.

The researchers concluded that HBF is a promising new treatment for COVID-19 because it has both antiviral and anti-inflammatory effects. They also suggested that further studies are needed to confirm the efficacy and safety of HBF in clinical trials.

Bioactive compounds from Huashi Baidu decoction possess both antiviral and anti-inflammatory effects against COVID-19

Haiyu Xu, Shufen Li, Jiayuan Liu, Jinlong Cheng, Liping Kang, Weijie Li, Yute Zhong, Chaofa Wei, Lifeng Fu, Jianxun Qi, Yulan Zhang, Miaomiao You, Zhenxing Zhou, Chongtao Zhang, Haixia Su, Sheng Yao, Zhaoyin Zhou, Yulong Shi, Ran Deng, Qi Lv, Fengdi Li, Feifei Qi, Jie Chen, Siqin Zhang, Xiaojing Ma, Zhijian Xu, Shao Li, Yechun Xu, Ke Peng, Yi Shi, Hualiang Jiang, George F Gao, Luqi Huang

Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2301775120

Significance Huashi Baidu decoction (Q-14), a famous traditional Chinese medicine decoction for COVID-19, has good effects on SARS-CoV-2 RNA clearance, promoting lung lesion opacity absorption, reducing inflammation, and ameliorating flu-like symptoms based on a series of clinical trials, having potent antiviral and antiinflammatory effects. However, due to the lack of systematic and in-depth research, little significant progress has been made in the study of TCMT-NDRD of HBF for COVID-19 management. Therefore, the aim of the current study was to identify key antiviral and anti-inflammatory bioactive compounds from HBF based on an integrative pharmacological strategy. These findings will greatly stimulate the traditional Chinese medicine theory-driven natural drug discovery against COVID-19 and promote the modern research of Chinese medicine.

References

Adams, Grosse-Kunstleve, Li, Ioerger, Terwilliger, PHENIX: Building new software for automated crystallographic structure determination, Acta Crystallogr. D

Al-Kuraishy, Sequential doxycycline and colchicine combination therapy in Covid-19: The salutary effects, Pulm. Pharmacol. Ther

Baell, Walters, Chemistry: Chemical con artists foil drug discovery, Nature

Bai, Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir, Signal Transduct. Targeted Ther

Bailey, The ccp4 suite -programs for protein crystallography, Acta Crystallogr. Sect. D

Bao, The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice, Nature, doi:10.1073/pnas.230177512011of11

Bernal, Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients, N. Engl. J. Med

Chen, 5-hydroxymethylcytosine signatures in circulating cell-free DNA as early warning biomarkers for COVID-19 progression and myocardial injury, Front. Cell Dev. Biol

Emsley, Cowtan, Coot: Model-building tools for molecular graphics, Acta Crystallogr. D

Feng, Li, Zhang, Yin, Li, Crystal structure of SARS-CoV 3C-like protease with baicalein, Biochem. Biophys. Res. Commun

Fu, Mechanism of microbial metabolite leupeptin in the treatment of COVID-19 by traditional Chinese medicine herbs, mBio

Gordon, Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency, J. Biol. Chem

Gottlieb, Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: A randomized clinical trial, Jama

Huang, Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China, Lancet

Huang, Traditional Chinese medicine (TCM) in the treatment of COVID-19 and other viral infections: Efficacies and mechanisms, Pharmacol. Therapeut

Ingolfsson, Phytochemicals perturb membranes and promiscuously alter protein function, ACS Chem. Biol

Koes, Baumgartner, Camacho, Lessons learned in empirical scoring with smina from the CSAR 2011 benchmarking exercise, J. Chem. Inf. Model

Li, Potential treatment of COVID-19 with traditional chinese medicine: What herbs can help win the battle with SARS-CoV-2?, Engineering

Li, SARS-CoV-2 Z-RNA activates the ZBP1-RIPK3 pathway to promote virus-induced inflammatory responses, Cell Res

Li, SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation, Signal Transduct. Target. Ther

Li, SFTSV infection induces BAK/BAX-dependent Mitochondrial DNA release to trigger NLRP3 inflammasome activation, Cell Rep

Liu, A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs, Cell Res

Liu, Combination of Hua Shi Bai Du granule (Q-14) and standard care in the treatment of patients with coronavirus disease 2019 (COVID-19): A single-center, open-label, randomized controlled trial, Phytomedicine

Liu, He, Huang, Wei, Zhu, Severe fever with thrombocytopenia syndrome, an emerging tick-borne zoonosis, Lancet. Infect. Dis

Liu, Herb-drug interactions involving drug metabolizing enzymes and transporters, Curr. Drug. Metab

Liu, SFTSV infection induced interleukin-1β secretion through NLRP3 inflammasome activation, Front. Immunol

Lyu, Traditional Chinese medicine in COVID-19, Acta Pharm. Sin. B

Mangalmurti, Hunter, Cytokine storms: Understanding COVID-19, Immunity

Maurice, Advances in targeting cyclic nucleotide phosphodiesterases, Nat. Rev. Drug. Discov

Minor, Cymborowski, Otwinowski, Chruszcz, Hkl-, The integration of data reduction and structure solution-from diffraction images to an initial model in minutes, Acta Crystallogr. D

Najjar-Debbiny, Effectiveness of paxlovid in reducing severe COVID-19 and mortality in high risk patients, Clin. Infect. Dis

Niu, Network pharmacology analysis to identify phytochemicals in traditional Chinese medicines that may regulate ACE2 for the treatment of COVID-19, Evid. Based Complement. Alternat. Med

Niu, Network pharmacology for the identification of phytochemicals in traditional Chinese medicine for COVID-19 that may regulate interleukin-6, Biosci. Rep

Peng, Structural and biochemical characterization of the nsp12-nsp7-nsp8 core polymerase complex from SARS-CoV-2, Cell Rep

Runfeng, Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2), Pharmacol. Res

Saravolatz, Depcinski, Sharma, Molnupiravir and nirmatrelvir-ritonavir: Oral Coronavirus disease 2019 antiviral drugs, Clin. Infect. Dis

Sen, Identification of potential edible mushroom as SARS-CoV-2 main protease inhibitor using rational drug designing approach, Sci. Rep

Shankar-Hari, Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis, Jama

Shi, D3Targets-2019-nCoV: A webserver for predicting drug targets and for multi-target and multi-site based virtual screening against COVID-19, Acta Pharm. Sin. B

Shi, Efficacy and safety of Chinese herbal medicine versus Lopinavir-Ritonavir in adult patients with coronavirus disease 2019: A non-randomized controlled trial, Phytomedicine

Su, Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease, Nat. Commun

Tan, A novel coronavirus genome identified in a cluster of pneumonia cases -Wuhan, China 2019-2020, China CDC weekly

Trott, Olson, AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J. Comput. Chem

Tu, The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine, Nat. Med

Wang, Artemisinin, the magic drug discovered from traditional Chinese medicine, Engineering

Wang, Deciphering the active compounds and mechanisms of HSBDF for treating ALI via integrating chemical bioinformatics analysis, Front. Pharmacol

Wang, Upgrade of macromolecular crystallography beamline BL17U1at SSRF, Nucl Sci. Tech

Wang, Zhang, Zhan, Gao, Screening out anti-inflammatory or anti-viral targets in Xuanfei Baidu Tang through a new technique of reverse finding target, Bioorg. Chem

Wegesser, Coppi, Harper, Paris, Minocherhomji, Nonclinical genotoxicity and carcinogenicity profile of apremilast, an oral selective inhibitor of PDE4, Regul. Toxicol. Pharmacol. RTP

Wei, Chemical profiling of Huashi Baidu prescription, an effective anti-COVID-19 TCM formula, by UPLC-Q-TOF/MS, Chinese J. Nat Med

Xiong, The effect of Huashibaidu formula on the blood oxygen saturation status of severe COVID-19: A retrospective cohort study, Phytomed. Int. J. Phytothera. Phytopharmacol

Xiong, Wang, Du, Ai, Efficacy of herbal medicine (Xuanfei Baidu decoction) combined with conventional drug in treating COVID-19: A pilot randomized clinical trial, Integra. Med. Res

Xu, A comprehensive review of integrative pharmacology-based investigation: A paradigm shift in traditional Chinese medicine, Acta Pharm. Sin. B

Xu, ETCM: An encyclopaedia of traditional Chinese medicine, Nucleic Acids Res

Yang, Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection, Comparat. Med

Yu, Ju, Ding, A nucleocapsid-based transcomplementation cell culture system of SARS-CoV-2 to recapitulate the complete viral life cycle, Bio Protocol

Zebda, Paller, Phosphodiesterase 4 inhibitors, J. Am. Acad. Dermatol

Zhang, Association between use of Qingfei Paidu Tang and mortality in hospitalized patients with COVID-19: A national retrospective registry study, Phytomedicine

Zhang, Dong, Li, Chen, Xu, Structure-aided identification and optimization of tetrahydro-isoquinolines as novel PDE4 inhibitors leading to discovery of an effective anti-psoriasis agent, J. Med. Chem

Zhang, Ibrahim, Gillette, Bollag, Phosphodiesterase-4 as a potential drug target, Expert. Opin. Ther. Targets

Zhang, Li, Zhang, Li, Liu, Design, synthesis, and biological evaluation of tetrahydroisoquinolines derivatives as novel, selective PDE4 inhibitors for antipsoriasis treatment, Eur. J. Med. Chem

Zhang, SoFDA: An integrated web platform from syndrome ontology to network-based evaluation of disease-syndrome-formula associations for precision medicine, Sci. Bull

Zhao, Chinese medicine formula huashibaidu granule early treatment for mild COVID-19 patients: An unblinded, cluster-randomized clinical trial, Front. Med

Zhou, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature

Zhu, A novel coronavirus from patients with pneumonia in China, N. Engl. J. Med

Zhu, Analyzing the potential therapeutic mechanism of Huashi Baidu Decoction on severe COVID-19 through integrating network pharmacological methods, J. Tradit. Complement. Med

Zumla, Hui, Perlman, Middle east respiratory syndrome, Lancet

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0